We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic, Brand ProAmatine Gap Could Leave Opening for Chelsea
Generic, Brand ProAmatine Gap Could Leave Opening for Chelsea
September 14, 2010
A planned withdrawal at the end of the month of generic and brand versions of the low blood pressure drug ProAmatine will likely boost the fortunes of Chelsea Therapeutics’ lead candidate.